Cardio Diagnostics Holdings, Inc. (CDIOW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cardio Diagnostics Holdings, Inc. (CDIOW) Healthcare & Pipeline Overview

Cardio Diagnostics Holdings, Inc. pioneers epigenetics-based clinical tests for cardiovascular disease, utilizing AI and genetic insights to offer advanced risk assessment and chronic care management solutions. The Chicago-based firm serves telemedicine, provider organizations, and employers with its innovative diagnostic platforms.

What Is the Investment Thesis for CDIOW?

Cardio Diagnostics Holdings, Inc. is positioned within the growing personalized medicine and preventative cardiovascular care market, leveraging its epigenetics-based diagnostic tests and AI-powered solutions. The company's offerings, including Epi+Gen CHD and PrecisionCHD, address a critical need for earlier and more precise cardiovascular risk assessment and detection. Key value drivers include the increasing demand for advanced diagnostic tools that integrate genetic and epigenetic insights, potentially leading to improved patient outcomes and reduced healthcare costs. Growth catalysts involve securing widespread clinical adoption of its platforms, expanding partnerships with telemedicine providers and diverse healthcare organizations, and enhancing its market reach within the employer segment. However, investors must consider the company's current financial profile, marked by a -40152.5% profit margin and -471.4% gross margin, indicating significant operational challenges and a high cash burn rate. The company's beta of 2.20 suggests higher volatility compared to the broader market. Sustained investment in research and development, coupled with effective commercialization strategies, will be crucial for demonstrating long-term viability and achieving profitability in a competitive landscape.

Based on FMP financials and quantitative analysis

CDIOW Key Highlights

Profit Margin of -40152.5% reflects significant operational losses and early-stage commercialization challenges.

• Gross Margin of -471.4% indicates that the cost of goods sold substantially exceeds revenue, highlighting the high cost structure relative to current sales.
• Beta of 2.20 suggests the stock is considerably more volatile than the overall market, indicating higher risk for investors.
• Focus on epigenetics-based clinical tests positions the company in the innovative and growing personalized medicine segment for cardiovascular disease.
• Development of AI-powered solutions and a SaaS platform (HeartRisk) demonstrates a commitment to technological advancement in diagnostics and chronic care management.

Who Are CDIOW's Competitors?

CDIOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CDIOW's Key Strengths?

Pioneering epigenetics-based clinical tests for cardiovascular disease, offering a differentiated approach.

• Leveraging AI and genetic insights for advanced risk assessment and chronic care management.
• Diverse product portfolio including diagnostic tests, a clinical intelligence platform, and research solutions.
• Addressing the growing demand for personalized medicine and preventative cardiovascular care.
• Headquartered in Chicago, a hub for medical innovation.

What Are CDIOW's Weaknesses?

Significantly negative profit margin (-40152.5%) and gross margin (-471.4%) indicating high costs relative to revenue.

• Relatively new entrant in a competitive and capital-intensive market, requiring substantial investment.
• Need to demonstrate widespread clinical adoption and secure partnerships for market expansion.
• Potential for high cash burn rate given current financial metrics.
• Small employee base (15 employees) may limit scalability and operational capacity.

What Could Drive CDIOW Stock Higher?

CDIOW catalyst: Successful securing of strategic partnerships with major telemedicine providers or large healthcare networks, which could significantly expand market reach and test adoption.

• Demonstrating widespread clinical adoption of Epi+Gen CHD and PrecisionCHD, evidenced by increasing test volumes and positive clinical outcomes data.
• Expansion of market reach into new geographic regions or additional segments of provider organizations and employer groups.
• Further development and enhancement of the Actionable Clinical Intelligence platform, leading to increased clinician engagement and improved chronic care management outcomes.

What Are the Key Risks for CDIOW?

Financial-distress signal — its Altman Z-Score of -1.42 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-82.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• The need to demonstrate widespread clinical adoption of its epigenetics-based platforms, as market acceptance is crucial for revenue growth and sustainability.
• High negative profit margin (-40152.5%) and gross margin (-471.4%) indicate significant operational losses and a potential for high cash burn rate, necessitating continuous funding.
• Intense competition within the cardiovascular diagnostics market from both established players and other innovative biotech companies, potentially limiting market share.
• Regulatory challenges and the complex reimbursement landscape for novel diagnostic tests, which could impede commercialization efforts and market access.
• The inherent volatility of the stock, indicated by a Beta of 2.20, suggests that the company's share price may experience larger swings compared to the broader market.

What Are the Growth Opportunities for CDIOW?

• **Expansion in Personalized Medicine Market:** The demand for personalized medicine, tailored to individual genetic and epigenetic profiles, is a significant growth driver. Cardio Diagnostics' epigenetics-based tests, such as Epi+Gen CHD and PrecisionCHD, directly address this trend by offering highly individualized risk assessments for cardiovascular disease. As healthcare shifts towards more precise and preventative approaches, the market for such advanced diagnostics is expected to grow substantially, potentially reaching tens of billions globally by the end of the decade. Cardio Diagnostics is well-positioned to capture a share of this expanding market by demonstrating superior predictive accuracy and clinical utility.
• **Penetration of Telemedicine and Provider Organizations:** The company serves telemedicine providers, concierge practices, longevity clinics, and risk-bearing provider organizations. The ongoing expansion of telemedicine and the increasing focus on preventative health within specialized clinics present a substantial opportunity. As these organizations seek innovative solutions to manage patient health and reduce long-term costs, Cardio Diagnostics' platforms offer valuable tools for early detection and chronic care management. Expanding partnerships and integration with these diverse provider networks could significantly broaden the company's market reach and revenue streams over the next 3-5 years.
• **Growth in Employer-Sponsored Health Programs:** Employer organizations are increasingly investing in employee wellness and preventative health programs to reduce healthcare costs and improve productivity. Cardio Diagnostics' cardiovascular risk assessment tools can be integrated into these programs, offering a proactive approach to managing employee heart health. This market segment represents a large, untapped opportunity for the company, as employers seek data-driven solutions to identify at-risk individuals and implement targeted interventions. Successful penetration into this market could provide a stable and recurring revenue base.
• **Leveraging Actionable Clinical Intelligence Platform:** The Actionable Clinical Intelligence platform, which provides new epigenetic and genetic insights to clinicians, represents a significant growth avenue. By offering tools that improve chronic care management, Cardio Diagnostics moves beyond just diagnostics to become an integral part of ongoing patient care. As healthcare providers increasingly rely on data-driven insights to optimize treatment plans and patient outcomes, the demand for such intelligence platforms will grow. Enhancing the platform's capabilities and demonstrating its impact on clinical decision-making can drive adoption and recurring subscription revenues.
• **Development of Research-Use-Only Solutions (CardioInnovate360):** The CardioInnovate360 solution, designed to support the discovery, development, and validation of novel biopharmaceuticals, positions Cardio Diagnostics within the pharmaceutical research and development ecosystem. As drug discovery for cardiovascular diseases continues, there is a constant need for advanced tools to assess and manage these conditions during research phases. By providing a valuable resource to biopharmaceutical companies, Cardio Diagnostics can generate revenue from research collaborations and potentially establish its technologies as industry standards for cardiovascular drug development, offering a long-term, high-value growth path.

What Threats Does CDIOW Face?

• Intense competition from established diagnostic companies and other biotech firms.
• Regulatory hurdles and lengthy approval processes for new medical diagnostic tests.
• Rapid technological advancements potentially rendering existing solutions obsolete.
• Challenges in securing adequate funding for ongoing research, development, and commercialization.
• Market acceptance and reimbursement challenges for novel diagnostic technologies.

What Are CDIOW's Competitive Advantages?

• Specialized focus on epigenetics-based diagnostics for cardiovascular disease, offering a unique approach.
• Integration of AI and machine learning into genetic information analysis for risk assessment.
• Proprietary clinical tests like Epi+Gen CHD and PrecisionCHD, developed in-house.
• Diverse product portfolio spanning risk assessment, detection, clinical intelligence, and research solutions.
• Targeting multiple customer segments, including telemedicine, specialized clinics, and employers, diversifying revenue potential.

What Does CDIOW Do?

Cardio Diagnostics Holdings, Inc., established in 2017 and headquartered in Chicago, Illinois, is a pioneering company dedicated to the development and commercialization of epigenetics-based clinical tests for cardiovascular disease. The company's core mission revolves around leveraging advanced scientific understanding of epigenetics and genetics to provide more precise and proactive diagnostic and risk assessment tools for coronary heart disease (CHD). Among its flagship offerings is Epi+Gen CHD, a clinical blood test designed to assess a patient's three-year symptomatic CHD risk, including the likelihood of heart attacks. Complementing this, PrecisionCHD offers an integrated epigenetic-genetic clinical blood test specifically for the detection of existing coronary heart disease. Beyond diagnostics, Cardio Diagnostics provides Actionable Clinical Intelligence, a sophisticated platform that delivers novel epigenetic and genetic insights directly to clinicians, aiming to enhance chronic care management strategies. The company also extends its expertise to the research community through CardioInnovate360, a research-use-only solution that supports the discovery, development, and validation of new biopharmaceuticals for cardiovascular disease assessment and management. Furthermore, Cardio Diagnostics has developed HeartRisk, a SaaS-based cardiovascular disease risk intelligence platform, broadening its service model. The company strategically targets a diverse client base, including telemedicine providers, various provider organizations such such as concierge practices, longevity clinics, and risk-bearing provider organizations, as well as employer organizations, positioning itself at the forefront of personalized and preventative cardiovascular care.

What Products and Services Does CDIOW Offer?

• Develops and commercializes epigenetics-based clinical tests for cardiovascular disease.
• Offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment blood test.
• Provides PrecisionCHD, an integrated epigenetic-genetic blood test for detecting coronary heart disease.
• Delivers Actionable Clinical Intelligence, a platform for clinicians to gain epigenetic and genetic insights for chronic care management.
• Supplies CardioInnovate360, a research-use-only solution for biopharmaceutical discovery and validation.
• Operates HeartRisk, a SaaS cardiovascular disease risk intelligence platform.
• Serves telemedicine providers, concierge practices, longevity clinics, and risk-bearing provider organizations.
• Targets employer organizations with its diagnostic and risk management solutions.

How Does CDIOW Make Money?

• Sells epigenetics-based clinical blood tests directly to healthcare providers and organizations.
• Generates revenue from subscriptions or licensing fees for its SaaS platform, HeartRisk.
• Offers research-use-only solutions to support biopharmaceutical discovery and development.
• Provides a platform for actionable clinical intelligence, potentially through service fees or integration partnerships.

What Industry Does CDIOW Operate In?

Cardio Diagnostics Holdings, Inc. operates within the rapidly evolving healthcare technology and biotechnology sectors, specifically targeting cardiovascular disease diagnostics. The industry is characterized by a strong push towards personalized medicine and preventative care, driven by advancements in genomics, epigenetics, and artificial intelligence. The global market for cardiovascular disease diagnostics is substantial and continues to grow, fueled by an aging population and increasing prevalence of heart conditions. Cardio Diagnostics differentiates itself by focusing on epigenetics-based tests, which offer a novel approach to risk assessment beyond traditional genetic markers. While the market is competitive, with established diagnostic companies and emerging biotech firms, Cardio Diagnostics aims to carve out a niche through its integrated epigenetic-genetic platforms. The demand for more accurate, non-invasive, and predictive diagnostic tools provides a significant tailwind for companies like Cardio Diagnostics, although widespread clinical adoption and reimbursement remain critical hurdles.

Who Are CDIOW's Key Customers?

• Telemedicine providers seeking advanced diagnostic tools.
• Provider organizations, including concierge practices and longevity clinics.
• Risk-bearing provider organizations focused on preventative care and cost management.
• Employer organizations implementing employee wellness and preventative health programs.

Company Profile

Cardio Diagnostics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Meeshanthini V. Dogan. CDIOW has traded publicly since 2022.

Return on equity for Cardio Diagnostics Holdings, Inc. stands at -82.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -81.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -99.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 17.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -109.9%, the inverse of the P/E and a quick read on earnings relative to price.

CDIOW Valuation & Market Position

With a $4.60M market cap, Cardio Diagnostics Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CDIOW's quantitative score of 45/100 is below the peer average of 76/100.

Quarterly Financial Performance: Cardio Diagnostics Holdings, Inc.

Revenue for Cardio Diagnostics Holdings, Inc. came in at $5K during Q2 2026, a 100.0% improvement versus the preceding quarter. The company recorded a net loss of $1.5M, with diluted EPS of $-0.51. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CDIOW averaged $-0.73 in diluted EPS.

Cardio Diagnostics Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.42 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Cardio Diagnostics Holdings, Inc. revenue of about $25.0M for fiscal 2026, with EPS near $-16.50.

CDIOW Financials

CDIOW Latest News

No recent news available for CDIOW.

CDIOW Analyst Consensus

CDIOW MoonshotScore

CDIOW Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources